Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
Melinda Cook, PharmD, BCOP
Advertisement
Articles by Melinda Cook, PharmD, BCOP
Advertisement
Latest Updated Articles
New Therapy for Chronic Graft-Vs-Host Disease: AxatilimabPublished: February 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5
